Sharp, part of UDG Healthcare plc

sharpservices.com

Sharp works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry. We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

COVID-19: VACCINE AND DRUG DEVELOPMENT UPDATES

BioTechniques | April 08, 2020

news image

Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...

Read More

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

news image

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More

Business Insights

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

news image

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More

Business Insights

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

news image

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More
news image

COVID-19: VACCINE AND DRUG DEVELOPMENT UPDATES

BioTechniques | April 08, 2020

Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...

Read More
news image

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More
news image

Business Insights

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More
news image

Business Insights

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us